DiaMedica Therapeutics Releases Preeclampsia White Paper And Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia
- Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central
- White Paper: The Potential of DM199 to Treat Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.